{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T06:39:27Z","timestamp":1787812767128,"version":"build-2784847793"},"reference-count":23,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2021,2,1]]},"DOI":"10.1001\/jamaoncol.2020.6741","type":"journal-article","created":{"date-parts":[[2020,12,30]],"date-time":"2020-12-30T19:16:19Z","timestamp":1609355779000},"page":"271","source":"Crossref","is-referenced-by-count":96,"title":["Effect of Capivasertib in Patients With an <i>AKT1 E17K<\/i>-Mutated Tumor"],"prefix":"10.1001","volume":"7","author":[{"given":"Kevin","family":"Kalinsky","sequence":"first","affiliation":[{"name":"Department of Medicine, Columbia University Irving Medical Center, New York, New York"},{"name":"Now with Winship Cancer Institute at Emory University, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangxin","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Dana-Farber Cancer Institute, Harvard T.H. Chan School of Public Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn K.","family":"McCourt","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Washington University School of Medicine in St Louis, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasgit C.","family":"Sachdev","sequence":"additional","affiliation":[{"name":"Department of Medicine, TGen\/HonorHealth Research Institute, Scottsdale, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith P.","family":"Mitchell","sequence":"additional","affiliation":[{"name":"Department of Medicine, Thomas Jefferson University Health, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Zwiebel","sequence":"additional","affiliation":[{"name":"Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Austin","family":"Doyle","sequence":"additional","affiliation":[{"name":"Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"McShane","sequence":"additional","affiliation":[{"name":"Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuli","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Dana-Farber Cancer Institute\u2013ECOG (Eastern Cooperative Oncology Group)\u2013ACRIN (American College of Radiology Imaging Network) Biostatistics Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Gray","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Dana-Farber Cancer Institute\u2013ECOG (Eastern Cooperative Oncology Group)\u2013ACRIN (American College of Radiology Imaging Network) Biostatistics Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry V.","family":"Rubinstein","sequence":"additional","affiliation":[{"name":"Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Patton","sequence":"additional","affiliation":[{"name":"Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Williams","sequence":"additional","affiliation":[{"name":"Division of Cancer Therapeutics and Diagnosis, Molecular Characterization and Assay Development Laboratory, Leidos, Frederick, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley R.","family":"Hamilton","sequence":"additional","affiliation":[{"name":"Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston"},{"name":"Department of Pathology, City of Hope National Medical Center, Duarte, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara A.","family":"Conley","sequence":"additional","affiliation":[{"name":"Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"O\u2019Dwyer","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyndsay N.","family":"Harris","sequence":"additional","affiliation":[{"name":"Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos L.","family":"Arteaga","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Texas Southwestern Simmons Cancer Center, Dallas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice P.","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith T.","family":"Flaherty","sequence":"additional","affiliation":[{"name":"Department of Medicine, Massachusetts General Hospital, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"7","key":"coi200100r1","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nrc839","article-title":"The phosphatidylinositol 3-kinase AKT pathway in human cancer.","volume":"2","author":"Vivanco","year":"2002","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"coi200100r2","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1111\/bcp.13021","article-title":"AKT in cancer: new molecular insights and advances in drug development.","volume":"82","author":"Mundi","year":"2016","journal-title":"Br J Clin Pharmacol"},{"issue":"7152","key":"coi200100r3","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/nature05933","article-title":"A transforming mutation in the pleckstrin homology domain of AKT1 in cancer.","volume":"448","author":"Carpten","year":"2007","journal-title":"Nature"},{"issue":"15","key":"coi200100r4","doi-asserted-by":"publisher","first-page":"6084","DOI":"10.1158\/0008-5472.CAN-07-6854","article-title":"An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.","volume":"68","author":"Stemke-Hale","year":"2008","journal-title":"Cancer Res"},{"issue":"3","key":"coi200100r5","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1158\/1078-0432.CCR-17-1597","article-title":"Validation of immunohistochemical assays for integral biomarkers in the NCI-MATCH EAY131 clinical trial.","volume":"24","author":"Khoury","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"1","key":"coi200100r6","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ccr.2010.05.023","article-title":"4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors.","volume":"18","author":"She","year":"2010","journal-title":"Cancer Cell"},{"issue":"16","key":"coi200100r7","doi-asserted-by":"publisher","first-page":"5049","DOI":"10.1158\/1078-0432.CCR-09-0632","article-title":"PIK3CA mutation associates with improved outcome in breast cancer.","volume":"15","author":"Kalinsky","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"3","key":"coi200100r8","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.ccell.2018.08.008","article-title":"The genomic landscape of endocrine-resistant advanced breast cancers.","volume":"34","author":"Razavi","year":"2018","journal-title":"Cancer Cell"},{"issue":"4","key":"coi200100r9","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1158\/1535-7163.MCT-11-0824-T","article-title":"Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background.","volume":"11","author":"Davies","year":"2012","journal-title":"Mol Cancer Ther"},{"issue":"11","key":"coi200100r10","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1158\/1535-7163.MCT-15-0230","article-title":"Tumors with AKT1E17K mutations are rational targets for single agent or combination therapy with AKT inhibitors.","volume":"14","author":"Davies","year":"2015","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"coi200100r11","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1158\/1535-7163.MCT-15-0143","article-title":"AKT antagonist AZD5363 influences estrogen receptor function in endocrine-resistant breast cancer and synergizes with fulvestrant (ICI182780) in vivo.","volume":"14","author":"Ribas","year":"2015","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"coi200100r12","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nrd4694","article-title":"NCI-MATCH trial pushes cancer umbrella trial paradigm.","volume":"14","author":"Mullard","year":"2015","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"coi200100r13","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"2","key":"coi200100r14","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.jmoldx.2016.10.007","article-title":"Analytical validation of the next-generation sequencing assay for a nationwide signal-finding clinical trial: Molecular Analysis for Therapy Choice clinical trial.","volume":"19","author":"Lih","year":"2017","journal-title":"J Mol Diagn"},{"issue":"20","key":"coi200100r15","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1200\/JCO.2017.73.0143","article-title":"AKT inhibition in solid tumors with AKT1 mutations.","volume":"35","author":"Hyman","year":"2017","journal-title":"J Clin Oncol"},{"issue":"4","key":"coi200100r16","first-page":"5","article-title":"Abstract P5-21-32: AZD5363 in combination with fulvestrant in AKT1-mutant ER-positive metastatic breast cancer.","volume":"78","author":"Smyth","year":"2018","journal-title":"Cancer Res"},{"issue":"4","key":"coi200100r17","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1158\/2159-8290.CD-19-1209","article-title":"Characteristics and outcome of AKT1E17K-mutant breast cancer defined through AACR Project GENIE, a clinicogenomic registry.","volume":"10","author":"Smyth","year":"2020","journal-title":"Cancer Discov"},{"issue":"5","key":"coi200100r18","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1093\/annonc\/mdz086","article-title":"BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population.","volume":"30","author":"Turner","year":"2019","journal-title":"Ann Oncol"},{"issue":"15","key":"coi200100r19","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1200\/JCO.2019.37.15_suppl.1005","article-title":"Capivasertib (AZD5363) plus fulvestrant versus placebo plus fulvestrant after relapse or progression on an aromatase inhibitor in metastatic ER-positive breast cancer (FAKTION): a randomized, double-blind, placebo-controlled, phase II trial.","volume":"37","author":"Jones","year":"2019","journal-title":"J Clin Oncol"},{"issue":"50","key":"coi200100r20","doi-asserted-by":"publisher","first-page":"7455","DOI":"10.1038\/sj.onc.1209085","article-title":"Perturbations of the AKT signaling pathway in human cancer.","volume":"24","author":"Altomare","year":"2005","journal-title":"Oncogene"},{"issue":"7403","key":"coi200100r21","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/nature11154","article-title":"Sequence analysis of mutations and translocations across breast cancer subtypes.","volume":"486","author":"Banerji","year":"2012","journal-title":"Nature"},{"issue":"7547","key":"coi200100r22","doi-asserted-by":"publisher","first-page":"E11","DOI":"10.1038\/nature14265","article-title":"MAGI3-AKT3 fusion in breast cancer amended.","volume":"520","author":"Mosquera","year":"2015","journal-title":"Nature"},{"issue":"47","key":"coi200100r23","doi-asserted-by":"publisher","first-page":"19368","DOI":"10.1073\/pnas.1204384109","article-title":"Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers.","volume":"109","author":"Parikh","year":"2012","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2774443\/jamaoncology_kalinsky_2020_oi_200100_1613590908.06447.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,20]],"date-time":"2021-02-20T23:38:02Z","timestamp":1613864282000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2774443"}},"subtitle":["NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial"],"short-title":[],"issued":{"date-parts":[[2021,2,1]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2020.6741","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2,1]]}}}